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Abstract 36 
 37 
BACKGROUND AND AIMS: During active inflammation tissue intraluminal 38 
intestinal pH is decreased in patients with inflammatory bowel disease (IBD). 39 
Acidic pH may play a role in IBD pathophysiology. Recently, proton sensing 40 
G-protein coupled receptors were identified, including GPR4, OGR1 (GPR68), 41 
and TDAG8 (GPR65). We investigated whether GPR4 is involved in intestinal 42 
inflammation. 43 
METHODS: The role of GPR4 was assessed in murine colitis models: chronic 44 
dextran sulphate sodium (DSS) administration and by crossbreeding into an 45 
IL-10 deficient background for development of spontaneous colitis. Colitis 46 
severity was assessed by body weight, colonoscopy, colon length, histological 47 
score, cytokine mRNA expression, and myeloperoxidase (MPO) activity. In the 48 
spontaneous Il-10-/- colitis model, the incidence of rectal prolapse and 49 
characteristics of lamina propria leukocytes (LPLs) were analyzed.  50 
RESULTS: Gpr4-/- mice showed reduced body weight loss and histology score 51 
after induction of chronic DSS colitis. In Gpr4-/- /Il-10-/- double knock-outs the 52 
onset and progression of rectal prolapse were significantly delayed and 53 
mitigated compared to Gpr4+/+ /Il-10-/- mice. Double knock-out mice showed 54 
lower histology scores, MPO activity, CD4+ T-helper cell infiltration, IFN-γ, 55 
iNOS, MCP-1 (CCL2), CXCL1 and CXCL2 expression compared to controls. 56 
In colon, GPR4 mRNA was detected in endothelial cells, some smooth muscle 57 
cells, and some macrophages. 58 
CONCLUSION: Absence of GPR4 ameliorates colitis in IBD animal models 59 
indicating an important regulatory rolein mucosal inflammation, thus providing 60 
a new link between tissue pH and the immune system. Therapeutic inhibition 61 
of GPR4 may be beneficial for the treatment of IBD. 62 
 63 
Key Words: G-protein coupled receptor; pH receptors; GPR4; IBD; animal 64 
model.  65 
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Abbreviations: CCL20, chemokine (C-C motif) ligand 20; CD, Crohn's 68 
disease; CD31, cluster of differentiation 31; COX-2, 69 
prostaglandin-endoperoxide synthase 2; CXCL1, chemokine (C-X-C motif) 70 
ligand 1; CXCL2, chemokine (C-X-C motif) ligand 2; DSS, dextran sulphate 71 
sodium; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPCR, 72 
G-protein coupled receptor; GPR4, G protein coupled receptor 4; H&E, 73 
hematoxylin and eosin; IBD, inflammatory bowel disease; ICAM-1, intercellular 74 
adhesion molecule 1; IFN-γ, interferon gamma; IL-10, interleukin 10; IL-18, 75 
interleukin 18; IL-6, interleukin 6; iNOS, nitric oxide synthase 2; LPLs, lamina 76 
propria leukocytes;  MCP-1, chemokine (C-C motif) ligand 2, CCL2; MEICS, 77 
murine endoscopic index of colitis severity, MPO, myeloperoxidase; OGR1, 78 
ovarian  cancer G protein coupled  receptor 68 (also Gpr68); OR, odds ratio; 79 
PBS, phosphate buffered saline; RT-PCR, reverse transcription polymerase 80 
chain reaction; α-SMA, α-smooth muscle actin; SELE, selectin, endothelial cell; 81 
TDAG8, T-Cell Death-Activated Gene 8 (also known as G-protein coupled 82 
receptor Gpr65); TNF, tumor necrosis factor; UC, ulcerative colitis; VCAM1, 83 
vascular cell adhesion molecule 1.  84 
 85 
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Introduction 88 
 89 
 A local acidification in the gut lumen as well as in the mucosa has been 90 
observed during intestinal inflammation and implicated in the pathogenesis 91 
and progression of inflammatory bowel disease (IBD). Fallingborg et al. 92 
reported that intraluminal colonic pH values in the proximal parts of the colon 93 
were significnatly lower in patients with active ulcerative colitis (UC) than in 94 
normal subjects (lowest values 2.3, 2.9, and 3.4) 1. Nugent and coworkers also 95 
reported a decrease of colonic luminal pH values to less than 5.5 in two out of 96 
six patients with active UC 2. Also in patients with active Crohn’s disease (CD) 97 
three out of four CD patients investigated had decreased pH values in the 98 
proximal colon (pH 5.3) and distal colon (pH 5.3) as compared to normal 99 
controls (pH 6.8) 2. While there is still some controversy about the range of the 100 
intestinal luminal pH in IBD patients 3,4, it is widely accepted that inflammation 101 
is accompanied by tissue acidification due to hypoxia and excessive 102 
production and insufficient elimination of glycolytic metabolites. This indicates 103 
that luminal and tissue pH is decreased during active IBD. The 104 
(patho)physiological impact of these observations, however, has remained 105 
incompletely understood to date. 106 
  107 
 G protein-coupled receptors (GPCR) play an important role in regulating 108 
intestinal functions and have been implicated in the development and course 109 
of IBD 5-6. Only recently, we found that the GPCR OGR1 (Ovarian cancer 110 
G-protein-coupled receptor 1, GPR68) plays a role in IBD and that genetic 111 
deletion of OGR1 partially prevents the development of colitis in the IL-10 112 
deficient IBD mouse model 7. The effects of OGR1 on intestinal function and 113 
inflammation may involve regulation of the intestinal barrier function 8. OGR1 114 
belongs to the same family of proton-activated G protein-coupled receptors as 115 
GPR4 9-11. A third family member is the T-cell death associated gene 8 (TDAG8, 116 
GPR65) 9-11. Accumulating evidence indicates that members of this family of 117 
GPCRs, namely GPR4, OGR1 and TDAG8, are activated by protons upon a 118 
decrease of pH. At pH 7.6 the receptors are almost silent, while at pH 6.8 they 119 
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are fully activated and thus may play a crucial role in pH homeostasis 9,11.  120 
  121 
 GPR4 activation is transduced via the Gas pathway, followed by 122 
intracellular cAMP accumulation 9,11. Half-maximal activation of cAMP 123 
formation by GPR4 expressed in HEK293 cells occurred at pH 7.55 11. Limited 124 
studies exist on the relationship between GPR4 and tumor development or 125 
regulation of metabolic acidosis in the kidney 12-18. The function of all three 126 
proton-activated receptors has been linked to inflammatory processes in 127 
various tissues 19 but the role of GPR4 in IBD is currently unknown. Gpr4 128 
mRNA was found to be widely expressed in a variety of tissues including small 129 
intestine, colon, and spleen, and localized to - among other cell types - 130 
endothelial cells throughout the body. In endothelial cells, activation of GPR4 131 
by extracellular acidification stimulates proinflammatory pathways and 132 
molecules involved in the adhesion of monocytes including CXCL2, CCL20, 133 
VCAM1, and SELE 20{Dong, 2013 #2467}{Tobo, 2015 #1}. Since GPR4 is 134 
expressed along the small and large intestine, we hypothesized that this 135 
proton-activated receptor might be involved in sensing local pH changes and 136 
may participate in the pathophysiology of IBD.  137 
  138 
 Therefore, we examined the role of GPR4 in two murine models of colitis in 139 
vivo, the dextran sulphate sodium (DSS) induced chronic colitis model and the 140 
spontaneous colitis model in IL-10 deficient animals. Collectively, these data 141 
demonstrate that absence of GPR4 is associated with ameliorated colitis, 142 
indicating that pH sensing plays an important role in the pathophysiology of 143 
IBD. 144 
 145 
 146 
 147 
 148 
 149 
                                                                                                   150 
 151 
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Methods and Materials 153 
 154 
Human colonic biopsies 155 
 Human colon biopsies were collected from patients during colonoscopy 156 
performed at the Division of Gastroenterology and Hepatology, University 157 
Hospital Zurich (Switzerland). CD patients (8 with severe, 7 with moderate 158 
inflammation and 14 in remission) and UC patients (5 with severe and 3 with 159 
moderate inflammation) underwent colonoscopy for assessment of 160 
inflammation. Biopsies from patients with colitis were taken from inflamed 161 
areas. The control biopsies (17 controls) were from subjects undergoing 162 
colonoscopy for screening for colorectal cancer. The protocol for the study was 163 
approved by the local Cantonal Ethics Committee Zurich, Switzerland.  164 
 165 
 166 
Induction of chronic colitis with DSS 167 
 Gpr4-/- mice (BALB/c and C57BL/6 background) were provided by Thomas 168 
Suply and Klaus Seuwen, Novartis, Basel 13,21. Gpr4-/- mice (C57BL/6) were 169 
bred to Il10-/- mice (C57BL/6) 22-24 with the goal to generate Gpr4 -/- /IL-10 -/- 170 
mice. All transgenic strains were bred in the standard animal facility of the 171 
Institute of Physiology, University of Zurich. Animal experiments were 172 
performed in the Zurich Integrative Rodent Physiology (ZIRP) core facility 173 
according to the guidelines of the Swiss animal welfare law and approved by 174 
the Cantonal Veterinary Office Zurich, Switzerland.  175 
Three experiments (2 experiments on a BALB/c and one on a C57/BL6 176 
background) were performed with DSS (MP Biomedicals, LLC, Solon, OH, 177 
USA) induced chronic colitis. Female mice at the age of 10-13 weeks and a 178 
body weight around 20 g were used in the experiment. Chronic colitis was 179 
induced in wild-type and Gpr4-/- mice with 4 cycles of 3 % DSS in drinking 180 
water for 7 days followed by 10 days of regular drinking water. After the last 181 
cycle all animals were allowed to recover for 5 weeks and subsequently 182 
sacrificed for sample collection. Mice on water served as controls throughout 183 
the experiments. 184 
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In the spontaneous IL-10 deficient colitis model, the onset and 185 
development of inflammatory markers, colitis and rectal prolapses were 186 
monitored over 200 days and data was analyzed using Kaplan-Meier analysis 187 
(log rank Mantel-Cox test). For the evaluation by histology, flow cytometry, and 188 
for the determination of cytokine (mRNA) expression profiles, some mice were 189 
sacrificed by cervical dislocation at 80 days of age. For all experiments 190 
wild-type littermates were used. 191 
 Histological analysis was performed as described previously 25-27. The 192 
sections were stained with hematoxylin and eosin (H&E) and scored by two 193 
independent researchers in a blinded fashion. 194 
Data for the DSS colitis model originate from one round of experiments 195 
with mice with the identical genetic background (littermates) but the other two 196 
rounds of experiments yielded qualitatively similar results. 197 
  198 
 199 
Genomic DNA extraction and genotyping  200 
 DNA extraction was done according to standard NaOH digestion. The PCR 201 
reactions used for GPR4 genotyping were set up with following 202 
oligonucleotides: 5’-atgggatcggccattgaacaa-3’ (TS426), 203 
5’-tcatcctgatcgacaagacc-3’ (TS427), 5’- gctgccatgtggactctcga-3’ (TS428), 204 
5’-caggaaggcgatgctgatat-3’ (TS429). TS426-TS427 is specific for neo (479 205 
bps), and TS428-TS429 is specific for the GPR4 allele (302 bps). IL-10 mice 206 
were screened with the following primers: forward 207 
5’-GTGGGTGCAGTTATTGTCTTCCCG-3’ (oIMR0086), reverse 208 
5’-GCCTTCAGTATA AAA GGGGGACC-3'.   209 
 210 
 211 
 212 
Assessment of colonoscopy score in mice 213 
 Mucosal damage was assessed by the murine endoscopic index of colitis 214 
severity (MEICS) as described previously 26-29. Animals were anaesthetized 215 
intraperitoneally with 90-120 mg of ketamine (Narketan 10%, Vétoquinol AG, 216 
Bern, Switzerland) and 8 mg of xylazine (Rompun 2%, Bayer, Zurich, 217 
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Switzerland) per kg body weight and examined by colonoscopy (Karl Storz 218 
Tele Pack Pal 20043020, Karl Storz Endoskope, Tuttlingen, Germany).  219 
 220 
Myeloperoxidase (MPO) activity assay 221 
 MPO activity was calculated by photoabsorbance, as previously described 222 
26-27. Briefly, colon tissues were homogenized in 50 mM phosphate buffered 223 
saline (PBS, pH 6.0) with 0.5% hexadecyltrimethylammonium bromide 224 
(H-5882, Sigma). After performing three cycles of freeze-and-thaw, 20 µl of the 225 
homogenates supernatant were mixed with 280 µl of 0.02% dianisidine 226 
(D-3252, Sigma) solution. After 20 min incubation at room temperature, 227 
absorbance was measured at 460 nm. Protein concentration of the colon 228 
tissue supernatant was determined by Bradford protein assay (Bio-Rad). MPO 229 
activity was calculated as mean absorbance/incubation time/protein 230 
concentration. 231 
 232 
RNA extraction and quantitative Real-Time RT-PCR 233 
 Total RNA was extracted from colon and mesenteric lymph nodes tissue 234 
using the Qiagen RNeasy Mini Kit at a Qiacube workstation (Qiagen; Hilden, 235 
Germany) according to the manufacturer’s instructions 26-27. cDNA was 236 
prepared from adjusted RNA samples (2 µg/20 µl reaction) using the TaqMan 237 
High Capacity Reverse Transcriptase Reagent Kit (Applied Biosystems; 238 
Forster City, CA, USA). Thermocycling conditions for reverse transcription 239 
were set at 25 °C for 10 minutes, 37 °C for 120 minutes, 85 °C for 5 seconds 240 
(TGradient thermocycler, Biomera; Goettingen, Germany).   241 
 Semi-quantitative RT-PCR Taqman assays (7900 Fast Real Time PCR 242 
system, Applied Biosystems; Forster City, CA, USA) were performed under the 243 
following cycling conditions: 20 seconds at 95 °C, then 45 cycles of 95 °C for 3 244 
seconds and 60 °C for 30 seconds with the TaqMan Fast Universal Mastermix. 245 
TaqMan assay probes for GPR4, TDAG8, OGR1, iNOS, IL-10, TNF-α, IFN-γ, 246 
IL-6, IL-18, MCP-1 (Life Technologies/ABI; Forster City, CA, USA) were used 247 
(Supplementary Table 1). RNA samples from individual animals were run in 248 
triplicates including a negative control (without cDNA). The comparative ΔCt 249 
method was applied to determine the quantity of the cytokines relative to the 250 
endogenous control Gapdh (mouse GAPDH, Mm03302249_g1, Reporter=VIC 251 
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and Quencher=MGB) and a reference sample. The relative quantification 252 
value was expressed and shown as 2−ΔCt. 253 
 254 
RNA in situ hybridization (RNAscope) and immunohistochemistry 255 
 Il-10-/- (C57BL/6) and Gpr4-/- mice (C57BL/6) were used to examine where 256 
Gpr4 mRNA is expressed in the murine proximal colon. C57BL/6 wild type 257 
mice were used as a wild-type reference (n=3 per strain). Proximal colon of 258 
isoflurane anesthetized mice was harvested and incubated for 24 hours in 4% 259 
paraformaldehyde/PBS. The PFA/PBS solution was replaced by 10% sucrose 260 
in PBS up to the tissue sink to the bottom of the container. This step was 261 
repeated with 20% and 30% sucrose solutions. Colon rings were cut and 262 
embedded in Optimal Cutting Temperature (OCT). Five μm sections were 263 
prepared on Superfrost microscope slides (Thermo Fisher Scientific, 264 
Braunschweig, Germany) and kept for up to one week at -80 °C. The RNA in 265 
situ hybridization was performed using the the RNAscope 2.5 HD assay, Red, 266 
and the RNAscope 2.0 HD detection kit, Brown (Advanced Cell Diagnostics, 267 
Hayward, CA, USA) following the manufacturer’s protocol. Briefly, slides were 268 
rehydrated in PBS and were incubated with pretreatment solutions at 269 
recommended temperatures. Four signal amplification steps were performed 270 
at 40°C and two additional steps at room temperature with the appropriate 271 
solutions and probes designed and provided by the supplier (Advanced Cell 272 
Diagnostics, Hayward, CA, USA). The fifth amplification step was extended 273 
from 30 min to one hour in order to enhance the chromogenic signal. Detection 274 
of chromogenic signal was performed for 10 min using the specific reagents for 275 
the Red or Brown kit. RNA in situ hybridization with the RNAscope 2.5 HD 276 
assay, Red was followed by immunohistochemistry for cluster of differentiation 277 
31 (CD31 or PECAM1), an endothelial marker, or immunofluorescence for 278 
α-Smooth Muscle Actin (α-SMA) or F4/80, a macrophage marker. Colon rings 279 
subjected to the combination of in situ hybridization for Gpr4 with 280 
immunofluorescence for F4/80 and αSMA were incubated for 75 min at room 281 
temperature either with 1:10 rat anti-mouse F4/80 (MCA497R, Bio-Rad, 282 
Cressier, Switzerland) or with 1:50 rabbit anti-αSMA (Ab5694, Abcam, 283 
Cambridge, UK). Next slides were washed twice in hypertonic PBS (18g NaCl/l) 284 
and once in normal PBS, for 5 min each step. Secondary antibodies were 285 
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added to the sections for one hour at room temperature. Sections stained for 286 
F4/80 were combined with 1:500 goat anti-rat IgG (H+L) cross-absorbed 287 
secondary antibody, Alexa Fluor 488 (A11006, Thermo Fisher Scientific, 288 
Braunschweig, Germany) and sections stained for αSMA were combined with 289 
1:500 donkey anti-rabbit IgG H&L, Alexa Fluor® 647 (ab150075, Abcam, 290 
Cambridge, UK). Slides were washed twice in hypertonic PBS and once in 291 
normal PBS, for 5 min each step and mounted with Dako glycergel mounting 292 
medium (Dako, Switzerland). 293 
Colon rings subjected to the combination of in situ hybridization for Gpr4 with 294 
immunohistochemistry for CD31, were incubated with Avidin/Biotin blocking 295 
reagents (Avidin/Biotin blocking kit, Vector Laboratories, Burlingame, CA, USA) 296 
and washed with PBS as described by the manufacturer. Next the tissue was 297 
incubated with 1:7 rat anti-mouse CD31 (550274, BD Pharmingen, USA) 298 
overnight at 4 °C, washed twice with PBS and incubated at room temperature 299 
for 30 min with 1:500 secondary antibody Biotin-SP-conjugated donkey anti-rat 300 
IgG (H+L) (Jackson ImmunoResearch, West Grove, PA, USA). The slides were 301 
washed twice in PBS and the immunohistochemical staining was obtained by 302 
incubating the colon sections for 30 min with Vecstatin Elite ABC reagent 303 
(Vector Laboratories, Burlingame, CA, USA). ABC solution was washed twice 304 
with PBS and replaced by DAB solution for 5 min (prepared as described by the 305 
manufacturer, Vector Laboratories, Burlingame, CA, USA). After washing for 5 306 
min in water, slides were counterstained  with hematoxylin I  and the slides 307 
were mounted with VectaMount Mounting Medium HT-5000 (Vector 308 
Laboratories, Burlingame, CA, USA). Slides subjected to RNA in situ 309 
hybridization with RNAscope 2.0 HD detection kit, Brown were counterstained 310 
directly after the detection of the chromogenic signal. 311 
 312 
Preparation of lamina propria lymphocytes (LPLs) 313 
 Lamina propria lymphocytes (LPLs) were isolated from Gpr4-/- /Il-10-/-, 314 
Gpr4+/+ /Il-10-/- and Gpr4+/+ /Il-10+/+  mice at 80 days of age following a 315 
modified protocol by Weigmann 30. Briefly, the dissected colon was washed 316 
with Ca+- and Mg+-free PBS. The tissue was cut and incubated in medium 317 
containing 20 mM EDTA (Sigma-Aldrich) for 30 min at 37° C under shaking. 318 
LPLs were isolated from the lamina propria by enzymatic digestion (in DMEM 319 
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medium containing 300 U/mL collagenase type I, 2 mg/mL Hyaluronidase, 0.3 320 
mg/ml DNase and 5 mM CaCl2.2H2O) for 15 min at 37 °C under shaking. The 321 
LPLs were purified by discontinuous Ficoll density-gradient centrifugation. 322 
 323 
Flow Cytometric Analysis (FACS) 324 
 Single cell suspensions from lamina propria (LP) of mice were prepared as 325 
described above and stained for analysis by flow cytometry using PBS 326 
containing 4% fetal calf serum and 2.5 mM EDTA. At least 0.5×106 LP 327 
cells/well were stained at 4°C in the dark with the following 328 
fluorochrome-labeled monoclonal antibodies (all from BD Biosciences): α-CD3, 329 
α-CD4, α-CD8, α-CD25, α-CD45.2, and α-CD161 (NK1.1). Viable cells were 330 
acquired on a FACS Canto II (BD Biosciences) and analyzed using FlowJo 331 
software (TriStar Inc). 332 
 333 
Statistical Analysis 334 
 Statistical analyses were performed using GraphPad Prism 5 (Version 335 
5.04, GraphPad Software Inc, San Diego, CA, US) and SPSS (8.0 for 336 
Windows; SPSS Inc, Chicago, IL, US). Groups of data were compared 337 
between genotypes using nonparametric Mann-Whitney U-test or 338 
Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple-comparison test. 339 
All data were expressed as the means ± SEM. Probabilities (p, two tailed) of p 340 
< 0.05 were considered statistically significant. Body weight comparison was 341 
performed using “General Linear Model, repeated measures”, and the full 342 
factorial model with type III sum of squares method 31. The “General Linear 343 
Model, repeated measures” integrated both “individual deviation of daily body 344 
weight” and “difference in genotype groups” into the analysis to avoid systemic 345 
bias 31.  346 
 For prolapse rate comparison studies, statistical differences between 347 
genotypes were calculated by chi-square test with Fisher’s exact test (exact 348 
significance, two sided) and risk estimate test from contingency table. The 349 
prolapse survival analysis was performed using Kaplan-Meier prolapse-free 350 
survival analysis (log-rank Mantel-Cox test) and estimated median 351 
prolapse-free survival time.  352 
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Results 354 
 355 
IBD patients show enhanced GPR4 mRNA expression compared to 356 
healthy controls  357 
According to the National Center for Biotechnology Information (NCBI) 358 
Gene Expression Omnibus (GEO) profile and Gene database 359 
(http://www.ncbi.nlm.nih.gov/sites/geo) 32 and the BioGPS database of The 360 
Scripps Research Institute (http://biogps.org)(e.g. GEO profile data set 361 
GDS3113 / 181558, GDS1096 / 211266_s_at, GDS1096 / 206236_at) 33,  the 362 
human small intestine and colon express GRP4 at moderate levels 363 
(supplementary figure 1). GPR4 mRNA expression in the colon of healthy 364 
subjects and IBD patients was confirmed by RT-qPCR. GPR4 expression was 365 
significantly higher in UC (n=8) and CD (n=29) patients compared to healthy 366 
controls (n=17) (3.9 -fold, P< 0.01; 4.2 -fold, P< 0.001, respectively. Figure 1A). 367 
These results suggest that GPR4 may play a role during inflammation. 368 
 369 
TDAG8 and OGR1 do not depend on GPR4 during DSS colitis in- mice  370 
In wild-type mice, DSS-induced chronic colitis caused no upregulation of 371 
Gpr4 mRNA expression in colonic tissue. While  similar results for the two 372 
other members of the pH receptor family, TDAG8 and OGR1, were found upon 373 
adiminstration of DSS in both Gpr4+/+ and Gpr4-/- mice (Figure 1B), which 374 
indicated that TDAG8 and OGR1 were not upregulated on mRNA level due to 375 
the lack of GPR4 in vivo.  376 
 377 
Lack of GPR4 reduces inflammation in the chronic DSS model with 378 
ameliorated body weight recovery  379 
Since GPR4 is expressed in human inflamed colonic tissue and 380 
proton-activated receptors have been linked to inflammatory diseases, we 381 
tested the impact of genetic deletion of GPR4 on the severity of chronic colitis 382 
in the DSS model. A total of 22 DSS treated Gpr4+/+ (16 BALB and 6 C57BL/6) 383 
mice and 18 DSS treated Gpr4-/- (11 BALB and 7 C57BL/6) mice in 3 384 
independent experiments were compared with 5 Gpr4+/+ and 6 Gpr4 -/- control 385 
mice (C57BL/6) receiving normal water. Compared with Gpr4+/+ mice, Gpr4-/- 386 
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mice showed less reduction in body weight upon DSS treatment (Fig. 2A). 387 
Gpr4 -/- mice lost clearly less body weight (on Day 62: 2.7% vs Gpr4+/+ + DSS 388 
mice: -1.5%) and from day 62 to day 83 showed an enhanced ability to regain 389 
weight (P< 0.05 *, Figure 2A). All 3 independent experiments showed similar 390 
results: Gpr4 -/- mice recovered with higher body weights indicating that GPR4 391 
deficiency ameliorated inflammation-associated body weight changes (P< 0.05 392 
for BALB (exp 1 and 2) and P< 0.01 ** for C57BL/6).  393 
 394 
Colonic specimens from all groups were analyzed for severity of 395 
inflammation by histological scoring by two blinded experts as described 396 
previously 8. The histological score was significantly lower in  Gpr4 -/- mice 397 
with DSS induced chronic colitis (Figure 2B,C and supplementary figure 2) 398 
compared to wild-type controls (2.3 ± 0.38 vs. 4.9 ± 0.81; P< 0.001)  399 
(supplementary figure 1A). DSS treated Gpr4-/- mice had lower scores for both 400 
epithelial injury and leukocyte infiltration (P< 0.001 each) (Figure 2B and 2C). 401 
All 3 experiments showed consistent results independent of genetic 402 
background. In contrast, DSS treated Gpr4-/- had slightly shorter colon lengths 403 
and a higher endoscopic MEICS score (P< 0.05, Supplementary Figure 3A 404 
and 3B). GPR4 deficiency did not influence MPO activity and spleen weight 405 
upon colitis induction (Supplementary Figure 3C and 3D). No differences in the 406 
cytokine expression profiles of iNOS, IL-10, TNF-α, IL-6, and MCP-1 from 407 
colon and mesenteric lymph nodes of DSS induced colitis Gpr4+/+ and Gpr4-/- 408 
mice were observed (Figure 3 and Supplementary Figure 3E). Only IFN-γ 409 
mRNA expression in colon samples was higher in Gpr4-/- mice treated with 410 
DSS compared to in wild-type mice receiving DSS (Figure 3). 411 
 412 
Spontaneous colitis in the IL-10 KO mouse is attenuated by GPR4 413 
deficiency 414 
The impact of GPR4 in colitis development was further assessed in the 415 
spontaneous colitis model in IL10 deficient animals. All mice were maintained 416 
in the same animal housing room and all experiments were carried out during 417 
the same time period. The occurrence of rectal prolapse as a sign of 418 
spontaneous colitis in Il-10-/- mice was monitored for 200 days. No prolapses 419 
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were observed in control Gpr4+/+ /Il-10+/+ mice in the breeding colonies for 200 420 
days (n > 100 for each gender). In comparison with Gpr4+/+ /Il-10-/- mice, both 421 
female and male Gpr4-/- /Il-10-/- mice, had a significantly lower rectal prolapse 422 
incidence (female: 6.9%, n = 29 vs. 66.7%, n = 12, P< 0.001, odds ratios of 423 
Gpr4-/-/Gpr4+/+ = 0.037 (95% CL 0.006-0.241); male: 24.4%, n=41 vs. 52.0%, 424 
n=25, P= 0.033, odds ratios = 0.298 (95% CL 0.103-0.859); chi-square test 425 
with Fisher’s exact test/two sided).  426 
Kaplan-Meier prolapse-free survival analysis showed a significantly 427 
delayed onset of rectal prolapse in Gpr4-/- /Il-10-/- mice as compared to Gpr4+/+ 428 
/Il-10-/- mice (estimated median prolapse-free survival time, female: >200 days 429 
vs. 123 days, P< 0.001; male: >200 days vs. 161 days, P= 0.007, log rank 430 
(Mantel-Cox) test, Figure 4A and Supplementary Figure 5A).  431 
Figure 4B (and Supplementary Figure 5B) illustrate the level of granulocyte 432 
infiltration as measured by MPO activity in colon tissue of mice at 80 days of 433 
age. This age was chosen as none of the mice had developed a prolapse at 434 
this age. In Gpr4-/- /Il-10-/- male mice, MPO activity was significantly lower than 435 
that in Gpr4+/+ /Il-10-/- male mice (0.013 ± 0.068 vs. 0.53 ± 0.101, P< .05). A 436 
similar trend was seen in female Gpr4-/- /Il-10-/- animals (Figure 4B).  437 
 438 
 Histological scoring by two blinded investigators of 80 days old mice 439 
showed that colons from male (histological score of 1.6 ± 0.91) and female (1.6 440 
± 0.93) Gpr4+/+ /Il-10+/+ mice were morphologically normal. Gpr4-/- /Il-10-/- male 441 
(2.3 ± 0.68) and female (2.6 ± 1.69) mice displayed significantly less mucosal 442 
injury and infiltration as compared to Gpr4+/+ /Il-10-/- male (6.3 ± 0.45) and 443 
female (6.5 ± 1.12) mice (P< 0.05 for both) (Figure 5A and B and 444 
Supplementary Figures 4 and 6), consistent with the prolapse ratio and 445 
prolapse-free survival analysis. 446 
 447 
 448 
Reduction of mucosal CD4+ T helper cell infiltrate upon Gpr4 deficiency 449 
Spontaneous colitis in IL-10 deficient mice is mediated by Th1 and Th17 450 
cell infiltration 34-35. In order to identify cellular players underlying the reduced 451 
colitis in Gpr4-/- mice we subsequently analyzed cellular infiltrates in the lamina 452 
propria by flow cytometry. As shown in Figure 6 and Supplementary Figure 6, 453 
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the percentage of total CD4+ cells and the CD4+ to CD8+ ratios in the lamina 454 
propria were significantly higher in Gpr4+/+ /Il-10-/- as compared to wild-type 455 
controls (P< .01, P< 0.001 and P< 0.001). Gpr4+/+ /Il-10-/- mice had significantly 456 
higher counts of CD4+ cells, but not of CD8+ cells in the lamina propria. The 457 
percentage of CD4+ of CD3+ was significantly lower in Gpr4-/- /Il10 -/- (P< 0.05, 458 
Figure 6) whereas no differences of regulatory T cells, natural killer cells, total 459 
CD45+ cells, monocytes/macrophages and neutrophils in LPLs composition 460 
were observed among the three groups (Supplementary Table 2).  461 
 462 
GPR4 modulates expression of factors involved in inflammation 463 
We further characterized mRNA expression of cytokines and other factors 464 
involved in cell adhesion and shown to be regulated by GPR436 in colon tissue 465 
and mesenteric lymph nodes using age-matched female (Figure 7 and 466 
Supplementary Figure 8) and male (Supplementary Figure 9) mice at 80 days 467 
of age. As shown in Figure 7, iNOS, IFN-γ, MCP-1, CXCL1, and CXCL2 mRNA 468 
expression was significantly lower in the colon of Gpr4-/- /Il-10-/- mice (P< .05), 469 
which reconfirmed reduced Th1-cell infiltrates in mice lacking GPR4. 470 
Furthermore, Gpr4-/- /Il-10-/- mice showed a trend for lower mRNA expression 471 
of IL-6, SELE, VCAM1 as compared to Gpr4+/+ /Il-10-/- mice (Figure 7 and 472 
Supplementary Figure 8). Male mice had similar patterns of changes in colon 473 
(Supplementary Figures 9). However, in lymph nodes from female and male 474 
mice no clear differences could be detected (Supplementary Figures 8B).  475 
 476 
Localization of Gpr4 mRNA in colon tissue 477 
Lastly, we performed chromogenic RNA in situ hybridization of Gpr4 478 
mRNA (RNAscope) in the proximal colon to examine where GPR4 may act to 479 
modulate inflammation. The tissue viability and assay quality were tested with 480 
the positive control Peptidyl-prolyl cis-trans isomerase B (Ppib) and a probe for 481 
the bacterial gene dihydrodipicolinatereductase (Dapb) (data not shown) was 482 
used as an additional negative control to Gpr4-/-. Wild-type and Il10-/- mice 483 
displayed chromogenic signals in lamina propria and muscularis (Figure 8 and 484 
Supplementary Figure 10), whilst the signal was absent from Gpr4-/- colon 485 
(supplementary Figure 11). Gpr4 mRNA related signal was prominent in cells 486 
lining small vessels consistent with the localization of Gpr4 in endothelial cells. 487 
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Signal intensity appeared to be higher in colon from Il10-/- mice and was also 488 
found in cells clustering in the interstitium. Costaining with CD31, a marker of 489 
endothelial cells, demonstrated partial colocalization of the Gpr4 signal with 490 
CD31. However, cells in the muscularis as well as clusters of interstitial cells, 491 
particularly abundant in colon from Il10-/- mice, were positive for Gpr4 and 492 
negative for CD31. (Figure 8). Further colocalization studies demonstrated 493 
partial colocalization of Gpr4 mRNA with α-smooth muscle actin, particularly 494 
seen in the muscularis layer (Figure 9A-D). Moreover, costainings with F4/80, 495 
a marker for macrophages, detected some macrophages with positive staining 496 
for Gpr4 mRNA (Figure 9E-H) both in the colon of WT and Il10-/- mice.  497 
498 
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Discussion 499 
 500 
This is the first detailed study on the (patho-)physiological function of the 501 
proton-activated G-protein coupled receptor GPR4 in the intestine and its 502 
impact on chronic intestinal inflammation. We demonstrate that GPR4 deletion 503 
protects against experimental colitis in both DSS-induced chronic colitis and 504 
the spontaneous colitis observed in IL-10 deficient mice.  505 
 506 
We show that GPR4 mRNA is expressed in the muscularis and lamina 507 
propria of colon and is strongly up-regulated in the colons of IBD patients. The 508 
localization based on mRNA in-situ hybridization is consistent with reports 509 
suggesting a predominant expression of GPR4 in endothelial cells 37. However, 510 
also smooth muscle cells in the muscularis and some macrophages showed 511 
expression of Gpr4. In the chronic DSS colitis model 34-35,38-39, Gpr4-/- mice lost 512 
less body weight and had lower histology scores compared to wild-type 513 
littermates indicating less severe inflammation. In the spontaneous IL-10 514 
deficient colitis model 22-24 lack of GPR4 significantly delayed onset and 515 
progression of rectal prolapses. As IL-10 is a well-known anti-inflammatory 516 
cytokine and suppressive for Th1 cells and macrophages 40, IL-10 knockout 517 
mice are thought to have a Th1-cell driven disease 34-35. Consistent with 518 
reduced Th1 cell infiltrates in Gpr4 -/- /IL-10 -/- mice, a significantly lower IFN-γ 519 
expression was found. Also, iNOS, MCP-1, CXCL1, and CXCL2 were reduced 520 
in the absence of GPR4. Further, flow cytometry analysis demonstrated that 521 
GPR4 knockout mice exhibit reduced infiltration of CD4+ T cells into the colon. 522 
The anti-inflammatory effect of GPR4 deficiency seemed not to be mediated 523 
by a regulatory T cell dependent mechanism as no significant differences in 524 
regulatory T cell numbers were observed between groups. However, we 525 
cannot exclude a functional change of regulatory T cells in GPR4-deficient 526 
animals. 527 
 528 
Therefore, activation of GPR4 is likely to exacerbate intestinal 529 
inflammation. Based on the expression of GPR4 in endothelial cells, the fact 530 
that GPR4 in a pH-dependent fashion triggers expression of pathways 531 
involved in cell adhesion and inflammation in endothelial cells, and that 532 
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endothelial cells can recruit and regulate inflammatory cells, we hypothesize 533 
that GPR4 may play a role in modulating inflammation in IBD. The 534 
down-stream signals may involve, among others,  the IFN-γ pathway. IFN-γ 535 
aggravates inflammation by increasing iNOS expression, activating 536 
macrophages and natural killer cells, favoring Th1 cell immune responses, and 537 
inducing apoptosis 41-42. Also, Gpr4 positive macrophages may contribute to 538 
inflammation. The role of Gpr4 in smooth muscle cells, however, remains 539 
elusive at this point. The excessive production of glycolytic metabolites in 540 
inflamed tissue causes the accumulation of protons, which may further activate 541 
GPR4, contributing to a positive feedback loop which may lead to a vicious 542 
cycle. Thus blockade of GPR4 may be a promising new target for IBD 543 
treatment. 544 
 545 
In vitro stimulation of GPR4 caused upregulation of many transcripts 546 
involved in inflammatory processes 36. Recent data published on Gpr4 -/- mice 547 
support the deleterious role of GPR4 activation during inflammation. Reduced 548 
immune responses and attenuated airway hyper-responsiveness were 549 
observed in GPR4 deficient mice following ovalbumin exposure 43. This was 550 
accompanied by a reduction in the number of eosinophils in broncho-alveolar 551 
lavage fluid 44. In the cigarette smoke-induced COPD mouse model, Gpr4 -/- 552 
mice had accelerated elimination of airway inflammation and enhanced 553 
neutrophil clearance 45. In patients with systemic sclerosis, expression of 554 
GPR4 correlates with the severity of lung disease 46. Similarly, a study 555 
published during the preparation of this manuscript describes a role of GPR4 556 
in aggravating the response to an acute DSS-mediated colonic chemical insult 557 
37.  558 
 559 
Yang et al. found evidence that acidosis/GPR4 signaling regulates 560 
endothelial cell adhesion mainly through the Gs/cAMP/Epac pathway 20. The 561 
activation of GPR4 by acidosis up-regulated the expression of multiple 562 
adhesion molecules such as SELE, VCAM-1 and ICAM-1 in vitro and 563 
increased the adhesiveness of human umbilical vein endothelial cells 564 
(HUVECs) expressing endogenous GPR4. These adhesion molecules are 565 
involved in the binding of leukocytes 20. In our studies Gpr4-/- /Il-10-/- mice 566 
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expressed lower mRNA levels of iNOS, TNF-α, IFN-γ, IL-6, MCP-1, CXCL2, 567 
CXCL1, SELE and VCAM-1 which at least in part is in agreement with the 568 
mentioned in vitro observations. A regulation of the NF-κB pathway by 569 
GPR4-dependent signaling has been postulated 36 further supporting our 570 
findings.  571 
 572 
In summary, our results demonstrate that GPR4- deficiency protects from 573 
experimental colitis in two different mouse models indicating an important 574 
pathophysiological role for the proton-activated receptor during the 575 
pathogenesis of mucosal inflammation. Future research needs to address the 576 
role of GPR4 in human IBD. Based on our mouse data, GPR4 may become a 577 
promising novel target for pharmacological IBD therapy.578 
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Figure legends 611 
 612 
Figure 1  613 
GPR4 mRNA detection in colonic tissue from humans and mice.  614 
(A) GPR4 mRNA was detected in colonic biopsies from controls (normal 615 
subjects), and patients with ulcerative colitis (UC), or Crohn’s disease (CD) by 616 
real-time RT-PCR Taqman assays. A minimum of 5 patients per group was 617 
tested for quantification. (B) Gpr4, Tdag8 and Ogr1 mRNA detection in colonic 618 
tissues from wild-type mice or Gpr4 -/- mice with water or DSS induced chronic 619 
colitis. Groups of data were compared between control group and different 620 
individual group using the non-parametric Kruskal-Wallis one-way ANOVA 621 
followed by Dunn’s multiple-comparison test. For quantification, values are 622 
mean ± SEM; n ≥ 5 per group; P<0.01 **, P < 0.001 ***. 623 
 624 
 625 
Figure 2  626 
Body weight loss analysis and histological assessment of colonic 627 
inflammation. 628 
(A) Gpr4 -/- mice, compared with Gpr4 +/+ mice, showed less relative body 629 
weight loss during DSS-induced chronic colitis. After 4 cycles of DSS 630 
treatment (last 22 days), Gpr4 -/- mice exhibited clearly reduced gain of body 631 
weight (F=2.980, P< .05 *) than Gpr4 +/+ mice. The body weight changes are 632 
expressed as relative change of body weight in % relative to day 0. Histology 633 
scores were analyzed to assess the epithelial damage (B) and leukocyte 634 
infiltration (C) indicating less severe inflammation in Gpr4 -/- mice with DSS. 635 
The right panel shows a representative histological section from wild-type or 636 
Gpr4 -/- mice treated with DSS, scale bar 100 µm. Data are representative of 3 637 
independent experiments each with 6-8 female mice/ group. 638 
 639 
 640 
 641 
 642 
Figure 3  643 
Assessment of the colitis severity during DSS induced chronic colitis. 644 
The mRNA expression levels of iNOS, IL-10, TNF-α, IFN-γ, IL-6, and MCP-1 in 645 
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colon from Gpr4 -/- mice and Gpr4 +/+ mice with or without administration of 646 
DSS were not changed between genotypes for the same treatment. For 647 
quantification, values are mean ± SEM; n ≥ 5 per group; P < 0.05 *, P < 0.01 **, 648 
P < 0.001 ***. Data are representative of 3 independent experiments. 649 
 650 
 651 
 652 
Figure 4  653 
Development of IBD and progression to prolapse were reduced by the 654 
deletion of GPR4 from IL10 deficient mice.  655 
(A) Kaplan-Meier prolapse-free survival curve showed delayed onset and 656 
progression of prolapses in female Gpr4-/- /Il-10-/- mice relative to female 657 
Gpr4+/+ /Il-10-/- mice (estimated median prolapse-free survival time, >200 days 658 
vs. 123 days, P< 0.001 ***, log rank (Mantel-Cox) test). Black dotted lines, 659 
Gpr4-/- /Il-10  -/- mice (6.9% prolapses, n=29, female); black solid line, Gpr4 +/+ 660 
/Il-10-/- mice (66.7% prolapses, n=12, female); grey dotted lines, Gpr4+/+ 661 
/Il-10+/+ mice (0% prolapses, n=31, female). No rectal prolapse was detected in 662 
the Gpr4+/+ /Il-10+/+ mice in these breeding colonies for 200 days (> 100 mice). 663 
Comparison of MPO activity in colon tissue (B), colon length (C), and relative 664 
spleen weight (D) showed attenuated colitis in female Gpr4-/- /Il-10-/- mice (not 665 
significant but relative spleen weight, P< 0.01 **, Kruskal-Wallis one-way 666 
ANOVA followed by Dunn’s multiple-comparison test). 667 
 668 
 669 
Figure 5  670 
Less histological damage in Gpr4-/- /Il-10-/- female mice.  671 
(A) The total histology scores of distal colon of female Gpr4-/- /Il-10-/-, Gpr4+/+ 672 
/Il-10-/- and Gpr4+/+ /Il-10+/+ mice at 80 days of age are shown, indicating 673 
reduced inflammation in Gpr4-/- /Il-10-/- mice (P< 0.05, Gpr4-/- /Il-10-/- compared 674 
to Gpr4+/+ /Il-10-/-).  (B) H&E stained sections showed the significant 675 
difference in the damage of epithelial integrity and intensity of the leukocyte 676 
infiltration into inflamed sites. Scale bar 100 µm. The total histology scores are 677 
representative for overall histology scores of distal colon (epithelial injury plus 678 
leukocyte infiltration). Data are presented as mean ± SEM; n ≥ 5 per group; P 679 
< 0.05 *, P <0 .01 **, P < 0.001 ***. 680 
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 681 
 682 
Figure 6  683 
Suppression of IFN-γ-producing CD4+ T helper cells in Gpr4-/- /Il-10-/- 684 
mice.  685 
LPLs were isolated from the colon of female Gpr4-/- /Il-10-/-, Gpr4+/+ /Il-10-/- and 686 
Gpr4+/+ /Il-10+/+ mice, stained to identify subpopulations and analyzed by flow 687 
cytometry. LPL profiles from flow cytometry analysis demonstrated that 688 
ablation of GPR4 suppressed accumulation of CD4+ (T helper) cells, mainly 689 
Th1 cells, but not CD8+ (T cytotoxic) cells: quantification of CD4+ T cells, 690 
percentage of CD4+ within CD3+ T cells, CD4+/CD8+ ratio, quantification of 691 
CD8+ T cells, and percentage of CD8+  within CD3+ T cells. The difference 692 
between Gpr4-/- /Il-10-/- and Gpr4+/+ /Il-10-/- did not reach statistical significance. 693 
Representative flow cytometry data of more than 5 qualitatively similar 694 
experiments are shown; isolated LPLs from 3 female mice were pooled in each 695 
group. Data are presented as mean ± SEM; P < 0.05 *, P < 0.01 **, P< 0.001 696 
***. 697 
 698 
 699 
Figure 7  700 
Analysis of mRNA expression profiles of cytokines in colon from Gpr4-/- 701 
/Il-10-/-, Gpr4+/+ /Il-10-/- and Gpr4+/+ /Il-10+/+ mice.   702 
The mRNA expression profiles of iNOS, IFN-γ, IL-6, MCP-1, CXCL1, and 703 
CXCL1 were analyzed by semi-quantitative RT-qPCR in colon tissue from of 704 
all three female strains (Gpr4-/- /Il-10-/-, Gpr4+/+ /I-10-/- and Gpr4+/+ /Il-10+/+ mice). 705 
Th1 associated IFN-γ expression was significantly lower in colon of female 706 
Gpr4-/- /IL-10-/- mice compared with female Gpr4+/+ /Il-10-/- mice (P< 0.05 *, 707 
Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple-comparison test). 708 
Data are presented as relative expression normalized to the house-keeping 709 
gene GAPDH, n = 6-9 mice per group. Data are presented as mean ± SEM; P 710 
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< 0.05 *, P < 0.01 **, P< 0.001 ***.  711 
 712 
 713 
Figure 8  714 
Localization of Gpr4 mRNA in endothelial cells in the colon from Gpr4+/+ 715 
and Il10-/- mice.  716 
Chromogenic in-situ hybridization of Gpr4 mRNA (red dots) in murine proximal 717 
colon using RNAscope. Sections were also labeled with antibodies against 718 
CD31, a marker of endothelial cells, showing partial colocalization with Gpr4. 719 
(A-C) Wild-type colon, (D-F) Colon from Il10-/-. Arrows indicate representative 720 
areas with Gpr4 mRNA expression. Scale bar 50 µm. Inserts show higher 721 
magnifications. 722 
 723 
Figure 9  724 
Localization of Gpr4 mRNA in smooth muscle cells and macrophages in 725 
the colon from Gpr4+/+ and Il10-/- mice.  726 
Fluorescent in-situ hybridization of Gpr4 mRNA (red dots) in murine proximal 727 
colon using RNAscope. (A-D) Sections were also labeled with antibodies 728 
against α-smooth muscle actin (green), a marker of smooth muscle cells 729 
showing partial colocalization with Gpr4. (E-H) Costaining for F4/80 (green), a 730 
marker for macrophages, detected staining of some macrophages, see insert. 731 
Nuclei were stained with DAPI (blue). Scale bar 50 µm. Inserts show higher 732 
magnifications. 733 
 734 
 735 
736 
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Supplement Table 1 List of TaqMan assay probes 
Gene 
Symbol Gene Name Assay ID 
GAPDH Mouse glyceraldehyde-3-phosphate dehydrogenase Mm03302249_g1 
GPR4 Mouse G protein coupled receptor 4 Mm00558777_s1 
TDAG8 Mouse TDAG8 (G protein coupled receptor 65) Mm00433695_m1 
OGR1 Mouse OGR1 (G protein coupled  receptor 68) Mm00558545_s1 
iNOS Mouse nitric oxide synthase 2 Mm01309893_m1 
IL-10 Mouse Interleukin 10 Mm00439615_g1 
TNF-α Mouse tumor necrosis factor alpha Mm99999068_m1 
IFN-γ Mouse interferon gamma Mm00801778_m1 
IL-6 Mouse Interleukin 6 Mm00446190_m1 
IL-18 Mouse Interleukin 18 Mm00434225_m1 
MCP-1 Mouse chemokine (C-C motif) ligand 2 Mm00441242_m1 
   
CXCL2 Mouse chemokine (C-X-C motif) ligand 2 Mm00436450_m1 
CCL20 Mouse chemokine (C-C motif) ligand 20 Mm01268754_m1 
CXCL1 Mouse chemokine (C-X-C motif) ligand 1 Mm04207460_m1 
SELE Mouse selectin, endothelial cell Mm00441278_m1 
VCAM1 Mouse vascular cell adhesion molecule 1 Mm01320970_m1 
COX-2 Mouse prostaglandin-endoperoxide synthase 2 Mm00478374_m1 
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Supplement Table 2 – Summary of flow cytometry data 
 
    
  Gpr4+/+ /Il-10+/+ Gpr4+/+ /Il10-/- Gpr4-/- /Il10-/- 
Total CD45+ leukocytes in LPL 311700 ± 67800  1293000 ± 545600  488200 ± 272800  
% CD45+ in viable single LPL 63.8 ± 8.4  83.7 ± 6.7  71.7 ± 12.2  
Total CD3+ T cells in LPL 77700 ± 21030  366600 ± 168000  125700 ± 64930  
% CD3+ in CD45+ 24.2 ± 3.7  29.0 ± 2.7  27.8 ± 3.0  
Total Treg cells in LPL 7249 ± 1325  22140 ± 3446  16300 ± 9012  
% Treg in CD4+ 35.9 ± 2.9  21.4 ± 2.6  24.3 ± 2.9  
 
 
Supplementary Table 2  
Analysis of T Cell Subsets in Gpr4+/+ /Il10+/+, Gpr4+/+ /Il10-/- and Gpr4-/- 
/Il10-/- mice.  
Female mice were sacrificed at 80~110 days and the tissues pooled from 3 
mice in each group. LPLs were stained with labeled antibodies and analyzed 
by flow cytometry as described in methods. Leukocytes were stained with APC 
conjugated anti-CD45.2 and T cell subsets identified by staining with FITC 
conjugated anti-CD3, PE conjugated anti-CD25, PB-Alexa 405 conjugated 
anti-CD4 and APC-Cy7 conjugated anti-CD8 and analyzed by flow cytometry. 
There were no statistics significance in total CD45+ T cells in LPLs, CD45 % in 
viable single LPLs, total CD3+ T cells in LPLs, CD3% in CD45+, total Treg cells 
in LPLs, Treg % in CD4+ between all three groups. Representative results of 
flow cytometric analysis of more than 5 independent experiments are shown. 
Data are presented as mean ± SEM. 
 
 
Supplementary Figure 1 
GEO profiles for GPR4 mRNA expression in various human tissues including 
small intestine and colon. Shown are data sets GDS3113/181558, 
GDS1096/211266_s_at, and GDS1096/206236_at. 
 
Supplementary Figure 2  
The total histology scores showed attenuated inflammation in Gpr4 KO 
mice upon DSS colitis.  
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(A) The total histology scores of distal colon for Gpr4+/+ + H2O, Gpr4-/- + H2O, 
Gpr4+/+ + DSS and Gpr4-/- + DSS mice are shown. The total histology scores 
are representative for overall histology scores of distal colon (epithelial injury 
plus leukocytes infiltration). Data are presented as mean ± SEM; n ≥ 5 per 
group; p <0.05 *, p <0.01 **, p <0.001 ***.  
 
 
Supplementary Figure 3  
Assessment of the colitis severity during DSS induced chronic colitis. 
Colon length, colonoscopy scores, relative spleen weight, myeloperoxidase 
(MPO) activity and mRNA expression profiles of cytokines were assessed in 
Gpr4+/+ and Gpr4-/- mice treated with water or DSS, respectively. Colon length 
(A) and colonoscopy scores (B) showed aggravated inflammation in Gpr4-/- 
mice upon DSS colitis. Gpr4+/+ and Gpr4 -/- mice showed similar relative spleen 
weight (spleen weight (g)/ Body weight (g) x 10-3) (C) and MPO activity in 
colonic tissue (D) upon DSS treatment. (E) The mRNA expression levels of 
iNOS, IL-10, TNF-α, IFN-γ, IL-6, IL-18 and MCP-1 in mesenteric lymph nodes 
from Gpr4-/- mice and Gpr4+/+ mice with or without administration of DSS were 
not changed. For quantification, values are mean ± SEM; n ≥ 5 per group; P < 
0.05 *, P < 0.01 **, P < 0.001 ***. Data are representative of 3 independent 
experiments. 
 
Supplementary Figure 4 
Less histological damage in Gpr4-/- /Il10-/- female mice.  
H&E stained sections showed the significant difference in the damage of 
epithelial integrity and intensity of the leukocyte infiltration into inflamed sites. 
The same sections are shown in higher magnifications in figure 5. Scale bar 
300 µm. 
 
Supplementary Figure 5  
Development of IBD and progression of prolapse differ between Gpr4-/- 
/Il10-/- and Gpr4+/+ /Il10-/- male mice.  
(A) Kaplan-Meier prolapse-free survival curve showed delayed onset and 
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progression of prolapse in male Gpr4-/- /Il10-/- mice relative to male Gpr4+/+ 
/Il10-/- mice (estimated median prolapse-free survival time, >200 days vs. 161 
days, ** p=0.007, log rank (Mantel-Cox) test). Black dotted lines, Gpr4-/- /Il10-/- 
mice (24.4% prolapses, n=41, male); black solid line, Gpr4+/+ /Il10-/- mice (52.0% 
prolapses, n=25, male); grey dotted lines, Gpr4+/+ /Il10+/+ mice (0% prolapses, 
n=26, male). Comparison of MPO activity in colon tissue (B), colon length (C) 
and relative spleen weight (D) showed attenuated colitis in male Gpr4-/- /Il10-/- 
mice (not significant but MPO activity, p<0.05 *, Kruskal-Wallis one-way 
ANOVA followed by Dunn’s multiple-comparison test). 
 
 
 
Supplementary Figure 6  
Reduction of histology scores in Gpr4-/- /Il10-/- male mice.  
(A) The total histology scores of distal colon for male Gpr4-/- /Il10-/-, Gpr4+/+ 
/Il10-/- and Gpr4+/+ /Il10+/+ mice at 80 days of age were shown, indicating 
reduced inflammation in Gpr4-/- /Il10-/- mice (p<0.05, Gpr4-/- /Il10-/- compared to 
Gpr4+/+ /Il10-/-). The total histology scores are representative for overall 
histology scores of distal colon (epithelial injury plus leukocytes infiltration). 
Data are presented as mean ± SEM; n ≥ 5 per group; p <0.05 *, p <0.01 **, p 
<0.001 ***. (B) H&E staining sections showed the significant difference in the 
damage of epithelial integrity and intensity of the leukocyte infiltration into 
inflamed sites. Scale bar 100 µm. 
 
 
Supplementary Figure 7  
Suppression of IFN-γ-producing CD4+ T helper cells in Gpr4-/- /Il10-/- mice. 
Dot plots of the expression of CD4+ vs. CD8+ in LPLs isolated from female 
Gpr4-/- /Il10-/-, Gpr4+/+ /Il10-/- and Gpr4+/+ /Il10+/+ mice are shown. LPLs were 
isolated and stained with anti-CD4 conjugated to PB-Alexa 405 and with 
anti-CD8 conjugated to APC-Cy7 and analyzed by flow cytometry. 
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Representative flow cytometry results from more than 5 qualitatively similar 
experiments are shown; isolated LPLs from 3 female mice were pooled in each 
group. 
 
 
Supplementary Figure 8  
Analysis of mRNA expression profiles of cytokines in colon and 
mesenteric lymph nodes in female Gpr4-/- /Il10-/- and Gpr4+/+ /ll-10-/- mice. 
(A) The mRNA expression profiles of IL-18, SELE, CCL20, VCAM-1, and 
COX-2 were analyzed by semi-quantitative RT-qPCR in colon tissue from of all 
three female strains (Gpr4-/- /Il10-/-, Gpr4+/+ /Il10-/- and Gpr4+/+ /Il10+/+ mice). (B) 
mRNA expression profiles of iNOS, TNF-α, IFN-γ, IL-6, CXCL1, CXCL2, 
CCL20, MCP-1, VCAm-1, COX-2 in lymph nodes from same animals. (P< 
0.05*, Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple-comparison 
test). Data are presented as relative expression normalized to the 
house-keeping gene GAPDH, n = 6-9 mice per group. Data are presented as 
mean ± SEM.  
 
Supplementary Figure 9  
The mRNA expression profile of cytokines in colon (A) and mesenteric 
lymph nodes (B) between Gpr4-/- /Il10-/- and Gpr4+/+ /Il10-/- male mice. 
iNOS, TNF-α, IFN-γ, IL-6, MCP-1, IL-18, CXCL2, CCL20, CXCL1, SELE, 
VCAM1 and COX-2 of all three male strains (Gpr4-/- /Il10-/-, Gpr4+/+ /Il10-/- and 
Gpr4+/+ /Il10+/+ mice) were determined by real time RT-PCR Taqman assay. 
Data represent copies of cytokine mRNA/GAPDH and mRNA amplification 
was representative of 6~9 mice per group. The homogenate of each mouse 
was tested in triplicates. Data are presented as mean ± SEM; p <0.05 *, p 
<0.01 **, p <0.001 ***. 
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Supplementary Figure 10 
Localization of Gpr4 mRNA in murine proximal colon of Gpr4-/- mice 
Chromogenic in-situ hybridization of Gpr4 mRNA (brown dots) in murine 
proximal colon using RNAscope. (A-B) Wildtype colon, (C,-D) Colon from 
Il10-/-. Scale bar 50 µm. 
 
Supplementary Figure 11 
Controls for localization of Gpr4 mRNA in murine proximal colon of 
Gpr4-/- mice 
 (A,B) In-situ hybridization of Gpr4 mRNA in the proximal colon of Gpr4-/- 
mice. No signal was detected. (C) To confirm the function of the RNAscope, 
mRNA of the ubiquitously expressed Peptidyl-prolyl cis-trans isomerase B 
(Pipb) was tested and detected. Scale bar 50 µm. 
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